Keyword: Gardasil

Merck's 2019 sales expectations are on the low side of what analysts expected, intensifying concerns about growth beyond I-O star Keytruda.

Among small batch of price increases for the pharma giant was a 1.5% increase on superstar cancer drug Keytruda and 6% on HPV shot Gardasil.

Samsung BioLogics faces potential delisting; Merck will increase Gardasil supply to China; Chinese officials mulls new regulation for vaccine.

Merck is increasing its HPV vaccine production capacity, but it still won't be enough to meet the full demand in China, a company spokesperson said.

Merck's Gardasil generated $1 billion in Q3, prompting an analyst to wonder just how much the shot might be able to generate in the long run.

CDC officials have been pushing HPV vaccination, and in 2017—just as in the previous four years—those efforts yielded only a slight increase.

Merck's HPV shot, Gardasil, continued to gain steam in the second quarter, and execs see "significant" growth prospects ahead.

Activists have railed at the U.K. government for refusing to offer Merck's HPV vaccine Gardasil to boys, but now the government has reversed its stance.

Here is some other vaccine news of note for the week.

Merck is seeking FDA approval to expand Gardasil 9's use in women and men ages 27 to 45.